Dual functional nanoparticles efficiently across the blood–brain barrier to combat glioblastoma via simultaneously inhibit the PI3K pathway and NKG2A axis

References

• Anestis DM, Tsitsopoulos PP, Ble CA, et al. Congenital glioblastoma multiforme: an unusual and challenging tumor. Neuropediatrics. 2017;48(6):403–412.
   PubMed Web of Science ®Google Scholar
• Scheuermann A, Belongia M, Lawlor MW, et al. Ganglioglioma in a survivor of infantile glioblastoma. J Pediatr Hematol Oncol. 2020;42:e56–e60.
   PubMed Web of Science ®Google Scholar
• Braunstein S, Raleigh D, Bindra R, et al. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol. 2017;134(3):541–549.
   PubMed Web of Science ®Google Scholar
• Delgado-López PD, Corrales-García EM, Martino J, et al. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. Clin Transl Oncol. 2017;19(8):931–944.
   PubMed Web of Science ®Google Scholar
• Camelo-Piragua S, Kesari S. Further understanding of the pathology of glioma: implications for the clinic. Expert Rev Neurother. 2016;16(9):1055–1065.
   PubMed Web of Science ®Google Scholar
• Dréan A, Goldwirt L, Verreault M, et al. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. Expert Rev Neurother. 2016;16(11):1285–1300.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang C, Wang L, et al. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment. Drug Deliv. 2019;26(1):551–565.
   PubMed Web of Science ®Google Scholar
• Chen C, Duan Z, Yuan Y, et al. Peptide-22 and cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB. ACS Appl Mater Interfaces. 2017;9(7):5864–5873.
   PubMed Web of Science ®Google Scholar
• Gao H, Qian J, Cao S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33(20):5115–5123.
   PubMed Web of Science ®Google Scholar
• Danhier F, Vroman B, Lecouturier N, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release. 2009;140(2):166–173.
   PubMed Web of Science ®Google Scholar
• Schnell O, Krebs B, Wagner E, et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008;18(3):378–386.
   PubMed Web of Science ®Google Scholar
• Fang Y, Jiang Y, Zou Y, et al. Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(ε-caprolactone) micelles. Acta Biomater. 2017;50:396–406.
   PubMed Web of Science ®Google Scholar
• Ma H, Hao P, Zhang L, et al. A new cyclic RGD peptide dimer for integrin αvβ3 imaging. Eur Rev Med Pharmacol Sci. 2016;20(4):613–619.
   PubMed Web of Science ®Google Scholar
• Maes W, Verschuere T, Van Hoylandt A, et al. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin Dev Immunol. 2013;2013:952469.
   PubMedGoogle Scholar
• Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434–452.
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res. 2008;28(2B):1143–1150.
   PubMed Web of Science ®Google Scholar
• Wu T, Du Y. LncRNAs: from basic research to medical application. Int J Biol Sci. 2017;13(3):295–307.
   PubMed Web of Science ®Google Scholar
• Grixti JM, Ayers D. Long noncoding RNAs and their link to cancer. Noncoding RNA Res. 2020;5(2):77–82.
   PubMed Web of Science ®Google Scholar
• Rathinasamy B, Velmurugan BK. Role of lncRNAs in the cancer development and progression and their regulation by various phytochemicals. Biomed Pharmacother. 2018;102:242–248.
   PubMed Web of Science ®Google Scholar
• Liu B, Cao W, Ma H. Knockdown of lncRNA LSINCT5 suppresses growth and metastasis of human glioma cells via up-regulating miR-451. Artif Cells Nanomed Biotechnol. 2019;47(1):2507–2515.
   PubMed Web of Science ®Google Scholar
• Kline C, Liu SJ, Duriseti S, et al. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018;140(3):629–638.
   PubMed Web of Science ®Google Scholar
• Kurz SC, Cabrera LP, Hastie D, et al. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018;91(14):e1355–e1359.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. Int Immunopharmacol. 2017;46:210–219.
   PubMed Web of Science ®Google Scholar
• Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018;24(1):47–53.
   PubMed Web of Science ®Google Scholar
• Mingari MC, Pietra G, Moretta L. Immune checkpoint inhibitors: anti-NKG2A antibodies on board. Trends Immunol. 2019;40(2):83–85.
   PubMed Web of Science ®Google Scholar
• Mahapatra S, Mace EM, Minard CG, et al. High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults. PLoS One. 2017;12(8):e0181134.
   PubMed Web of Science ®Google Scholar
• Rapaport AS, Schriewer J, Gilfillan S, et al. The inhibitory receptor NKG2A sustains virus-specific CD8+ T cells in response to a lethal poxvirus infection. Immunity. 2015;43(6):1112–1124.
   PubMed Web of Science ®Google Scholar
• Wang W, Li M, Zhang Z, et al. Design, synthesis and evaluation of multi-functional tLyP-1-hyaluronic acid-paclitaxel conjugate endowed with broad anticancer scope. Carbohydr Polym. 2017;156:97–107.
   PubMed Web of Science ®Google Scholar
• André P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–1743.
   PubMed Web of Science ®Google Scholar
• Soni K, Mujtaba A, Akhter MH, et al. Optimisation of ethosomal nanogel for topical nano-CUR and sulphoraphane delivery in effective skin cancer therapy. J Microencapsul. 2020;37(2):91–108.
   PubMed Web of Science ®Google Scholar
• Habban Akhter M, Sateesh Madhav N, Ahmad J. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1188–1198.
   PubMed Web of Science ®Google Scholar
• Akhter MH, Rizwanullah M, Ahmad J, et al. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol. 2018;46(5):873–884.
   PubMed Web of Science ®Google Scholar
• Akhter MH, Amin S. An investigative approach to treatment modalities for squamous cell carcinoma of skin. Curr Drug Deliv. 2017;14(5):597–612.
   PubMed Web of Science ®Google Scholar
• Akhter MH, Kumar S, Nomani S. Sonication tailored enhance cytotoxicity of naringenin nanoparticle in pancreatic cancer: design, optimization, and in vitro studies. Drug Dev Ind Pharm. 2020;46(4):659–672.
   PubMed Web of Science ®Google Scholar
• Feng X, Yao J, Gao X, et al. Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry, tumor neovasculature, and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces. 2015;7(50):27885–27899.
   PubMed Web of Science ®Google Scholar
• Sinha VR, Bansal K, Kaushik R, et al. Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm. 2004;278(1):1–23.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496–504.
   PubMed Web of Science ®Google Scholar
• Liu J, Shapiro JI. Endocytosis and signal transduction: basic science update. Biol Res Nurs. 2003;5(2):117–128.
   PubMedGoogle Scholar
• Gu Y, Chen T, Li G, et al. LncRNAs: emerging biomarkers in gastric cancer. Future Oncol. 2015;11(17):2427–2441.
   PubMed Web of Science ®Google Scholar
• Mansoori Y, Tabei MB, Askari A, et al. Expression levels of breast cancer-related GAS5 and LSINCT5 lncRNAs in cancer-free breast tissue: Molecular associations with age at menarche and obesity. Breast J. 2018;24(6):876–882.
   PubMed Web of Science ®Google Scholar
• Kong D, Li C, Yang Q, et al. Long noncoding RNA LSINCT5 acts as an oncogene via increasing EZH2-induced inhibition of APC expression in osteosarcoma. Biochem Biophys Res Commun. 2018;507(1-4):193–197.
   PubMed Web of Science ®Google Scholar
• Li R, Li X, Ning S, et al. Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3. PloS One. 2014;9(7):e101903.
   PubMed Web of Science ®Google Scholar
• Godlewski J, Nowicki MO, Bronisz A, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010;37(5):620–632.
   PubMed Web of Science ®Google Scholar
• Tian Y, Nan Y, Lei H, et al. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human human glioma. Int J Oncol. 2012;40(4):1105–1112.
   PubMed Web of Science ®Google Scholar
• Bhagat M, Halligan S, Sofou S. Nanocarriers to solid tumors: considerations on tumor penetration and exposure of tumor cells to therapeutic agents. Curr Pharm Biotechnol. 2012;13(7):1306.
   PubMed Web of Science ®Google Scholar
• Hu Q, Gu G, Liu Z, et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials. 2013;34(4):1135–1145.
   PubMed Web of Science ®Google Scholar